Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand in the cannabis industry. In addition to the Hightimes.com domain, the transaction also includes the trademarks for the Cannabis Cup and 420.com brands and their respective domain names. In exchange, High Times will receive a 19.9% stake in Lucy’s outstanding stock as well as performance-based payments.
“Lucy expects this acquisition to drive high margin revenue quickly and sustainably across the cannabis sector around the world. This is a great opportunity to grow the market presence of the nearly 50-year-old High Times brand globally through licensing and online distribution,” Lucy Scientific Discovery Executive Chairman and CEO Richard Nanula stated in the news release. “We are confident that this opportunity can add significant value for our shareholders.”
In addition, Lucy Scientific Discovery (NASDAQ: LSDI) was featured in a Financial News Media article together with other companies active in the burgeoning global cannabis market, including SNDL Inc. (NASDAQ: SNDL), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), and Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY). The piece discusses opportunities in the market driven by increased legalization of cannabis and rising acceptance of its use for medical purposes. Statista projects that revenue in the global cannabis market is projected to reach US$51.27 billion in 2023, at an annual growth rate (“CAGR” 2023-2028) of 14.95%, resulting in a market volume of US$102.90 billion by 2028.
To view the full press release/article, visit https://ibn.fm/OTHhn and https://ibn.fm/smu62
About Lucy Scientific Discovery Inc.
Lucy Scientific Discovery is a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly-owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver, and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com
